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PSYCHOTROPIC PHARMACOGENOMIC TESTING: EFFECTS ON PROVIDER 
PRESCRIBING PATTERNS AND PHQ-9 DEPRESSION SCREENING SCORES IN A 
RURAL MICHIGAN FAMILY PRACTICE 
By 
Nicole Marie Madalinski 
The rate of depression across the United States is on the rise with over 16.2 million 
people experiencing a depressive episode per year (Siu & and the US Preventive Services 
Task Force [USPSTF], 2016).  Medications to treat depression typically take weeks or 
months to see clinical improvement (Uphold & Graham, 2013).  If the medication is not 
effective, a dose or medication change may occur, lengthening the time spent in a 
depressive state.  This scholarly project retrospectively analyzed charts at a rural primary 
care practice that implemented GeneSight® psychotropic pharmacogenomic testing for 
treatment resistant depression.  This project sought to understand if PHQ-9 depression 
scores were impacted by pharmacogenetic testing.  Comparison of PHQ-9 scores across 
the two measurement periods during the study period was completed by using a paired t-
test.  The mean PHQ-9 scores decreased from 7 to 3.5 which did not reach a level of 
statistical significance.  A comparison of the total number of visits for depression in the 
control and test group patients was completed by using independent samples t-test which 
showed no significant difference in mean number of visits.  A major limitation of this 





literature and project findings support the need for further research on the implementation 
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Introduction to the Problem 
 Major depressive disorder is the leading cause of disability in adults in high-
income countries (Siu & USPSTF, 2016).  In 2016, the National Survey on Drug Use and 
Health (NSDUH) identified 16.2 million adults in the United States that had at least one 
episode of depression (National Institute of Mental Health, 2017).  With such a large 
number of people experiencing at least one depressive episode, primary care providers 
are taking on more and more responsibilities with prescribing antidepressants.  Of the 
16.2 million people identified during the NSDUH survey, only 44% pursued help from a 
healthcare professional and received a prescription (National Institute of Mental Health, 
2017).  Furthermore, over the course of one week, nurse practitioners in Tennessee 
reported that one-third of their patients were seen for mental health concerns (Shell, 
2001). 
Rural health is a growing topic of concern, notably with the lack of mental health 
providers available.  A survey of 140 rural Midwest women found that 36.4% (51 
participants) self-reported themselves as depressed (Groh, 2013).  The women of the 
study also completed a Center for Epidemiologic Studies-Depression Scale (CES-D) 
which defined depression as a score greater than or equal to 16 (Groh, 2013).  Out of the 
51 that self-reported as depressed, only 30 scored a 16 or greater on the CES-D 
confirming their self-report of depression (Groh, 2013).  This study identified that there 
was an incongruence in depression reporting among some of the women (Groh, 2013).  




and their CES-D scores (Groh, 2013).  This study supports the need to screen every 
patient for depression using a reliable and valid tool. 
 There are a variety of reliable and validated tools for depression screening in the 
primary care setting.  Depression screening is a Category B recommendation from the 
U.S. Preventive Services Task Force that recommends pregnant women, postpartum 
women, and the general adult population should be screened for depression (Siu & 
USPSTF, 2016).  For the purpose of this scholarly project, the nine question Patient 
Health Questionnaire (PHQ-9) is the main depression screening tool discussed as it is 
utilized at the clinical site where the project occurred.  This tool is self-administered by 
the patient and involves answering questions regarding depressive symptoms using a 
scale ranging from 0-3.  The PHQ-9 was found to be a reliable and validated tool for 
depression screening and was preferred over other tools that had similar reliability and 
validity (Kroenke, Spitzer, & Williams, 2001; Milette, Hudson, Baron, & Thombs, 2010). 
Prescribing Antidepressants 
 The family nurse practitioner role in treating depression has increased as the 
incidence of depression rises and the number of specialty providers decrease.  When 
considering prescribing antidepressants, there are many items to take into consideration.  
The provider must consider what symptoms the patient is having, what other medications 
they are taking, and the potential side effects that may be experienced.  A 2001 study 
discovered that 25 out of 44 nurse practitioners surveyed felt they needed additional 
education on prescribing antidepressants (Shell, 2001).   
There are four common classes of antidepressants prescribed, with a fifth class 




practitioners, the most common antidepressant classes prescribed were selective serotonin 
reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitor (SNRIs) 
(Burman, McCabe, & Pepper, 2015).  After the provider selects a medication, there needs 
to be consistent follow-up to assess the patients’ response to the medication including 
side effects and symptom improvement.  It is important to note that it may take up to 12 
weeks to notice any significant improvement in symptoms (Uphold & Graham, 2013).  
With the large number of potential medications that could be prescribed and the variety 
of side effects a person may have, the field of psychotropic pharmacogenomic testing 
may be helpful to the prescribing provider. 
Pharmacogenomic Testing 
 Pharmacogenomics are defined as, “the quantitative study of how genetics affects 
host responses to drugs” (Cascorbi, Bruhn, & Werk, 2013, p. S17).  Within the literature, 
the distinction between pharmacogenetics and pharmacogenomics is not clearly identified 
(Brennan, 2015).  One article distinguished pharmacogenetics as the individual genetic 
variation and gene expression from pharmacogenomics which was stated to be the 
broader topic of the entire genome (Brennan, 2015).  With the increasing rates of 
depression, primary care providers need to be aware of the tools that are available to use 
in their practice to help guide their medication decisions. 
 GeneSight® Psychotropic is pharmacogenomic test that analyzes genetic material 
obtained from a buccal mucosa swab.  The test analyzes 12 genes and how they affect 
individual patient responses to over 55 different psychotropic medications (GeneSight, 
2018).  The provider receives a report that places each medication into one of the 




significant gene-drug interaction (red) (GeneSight, 2018).  If a medication is placed in the 
yellow or red group, additional information regarding the reason why is provided at the 
bottom of the report.  Based on these results, the provider can choose an appropriate 
medication specific to their genetic analysis.   
Research Question 
 The purpose of this scholarly project was to assess how or if pharmacogenomic 
testing had any effect on prescribed practices or patient PHQ-9 scores.  The specific 
research questions asked were:  
1. As compared to a control group, what effect, if any, does utilizing GeneSight® 
Psychotropic pharmacogenomic testing have on prescribing patterns of primary 
care providers? 
2. What effect, if any, did medication changes as a result of GeneSight® 
Psychotropic pharmacogenomic testing have on PHQ-9 depression screening 
scores? 
Theoretical Framework 
 The theoretical framework applied to this scholarly project was the health belief 
model.  The health belief model is a psychological model that was developed in the 1950s 
to help explain why people engage in certain health behaviors and to help improve the 
use of preventative services (Rosenstock, 1974).  There are six concepts this model 
applies to health behaviors.  The six concepts include:  perceived susceptibility of the 
health problem, perceived severity, perceived benefits, perceived barriers, cues to action, 
and self-efficacy (Castonguay, Filer, & Pitts, 2016; Garner, 2014).  A patient’s opinion 




susceptibility (Garner, 2014).  The perceived severity is how severe the patient considers 
their diagnosis of depression to be and how severe the potential consequences may be 
(Garner, 2014).  The perceived benefit is how the patient believes a suggested action will 
help them, such as taking antidepressants or completing pharmacogenomic testing 
(Garner, 2014).  The patient is also expected to have concerns about the treatment which 
are known as the perceived barriers (Garner, 2014).  Cues to action refers to when the 
patient decides to act on the treatment plan or on their depressive symptoms (Garner, 
2014).  The final concept is self-efficacy, which is the patients belief that he/she can 
influence their own health by taking a positive action (Garner, 2014).  This model assists 
in explaining how patients and providers can utilize the theory behind the health belief 
model to help prevent or treat depression with pharmacogenomic testing. 
Significance for the Population 
 Diagnosing and treating depression is a common occurrence for a primary care 
provider and is a multifaceted process.  The PHQ-9 is a valuable depression screening 
tool for the primary care provider.  The PHQ-9 provides a score that allows the primary 
care provider to assess the patients level of depression and can be utilized to monitor 
treatment effectiveness (Löwe, Unützer, Callahan, Perkins, & Kroenke, 2004).  The 
primary care provider and the patient together create a treatment plan, which may include 
prescribing an antidepressant medication.  Prior to pharmacogenomic testing, the 
provider had to choose an antidepressant medication based off of recommended treatment 
guidelines, previous patient experiences with antidepressant medications, and symptoms 




patient can effectively choose an antidepressant medication based from the test results.  A 






 A review of the literature was completed using a variety of scholarly resources.  
CINAHL, PubMed, PsycINFO, and Google Scholar were all research search engines 
utilized for this review.  The literature review time frame was generally limited to the last 
10 years; however, some historical studies were also utilized from greater than 10 years 
ago.  The topics of depression and depression screening, prescribing practices, and 
pharmacogenomic testing were searched using the following key words: depression, 
PHQ-9, family nurse practitioner prescribing practices, pharmacogenomic testing, 
pharmacogenetic testing, and personalized medicine. 
Depression 
 Depression in the United States is a one of the most common mental health 
disorders (National Institute of Mental Health, 2017).  The statistics reveal the extent that 
depression effects individuals, families, and entire communities.  The 2016 National 
Survey on Drug Use and Health (NSDUH) discovered that 6.7% or 16.2 million adults in 
the United States experienced depression or a depressive episode at least once during the 
year (National Institute of Mental Health, 2017).  Suicide is the second leading cause of 
death in the world for the 15 to 29 year old age group with nearly 800,000 total deaths 
each year (World Health Organization, 2018).  In 2016, there were nearly 45,000 deaths 
due to suicidal actions in the United States (Centers for Disease Control and Prevention, 
2018). 
Despite the increasing numbers that are associated with depression, treatment 




help from a health professional and received medication; 37% did not receive any type of 
treatment (National Institute of Mental Health, 2017).  The National Health and Nutrition 
Examination Survey (NHNES) between the years of 2013 and 2016 had 20,146 
participants complete a public health survey (Centers for Disease Control and Prevention, 
National Center for Health Statistics, 2014, 2016).  The NHNES survey discovered that 
women were nearly twice as likely to have a depressive episode (Brody, Pratt, & Hughes, 
2018).  The data from the NHNES interviews also showed that the prevalence of 
depression did not differ with age and was the lowest in Non-Hispanic Asian adults 
(Brody et al., 2018).   
Depression can present itself in many different ways and there are a wide variety 
of depression symptoms that patients may experience.  The symptoms of depression 
include feelings of sadness, a decrease in energy levels, weight loss or gain, and recurrent 
thoughts of death or suicidal ideation (Mayo Clinic Staff, 2018).  The Diagnostic and 
Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric 
Association, 2013) breaks down depression disorders into seven categories that each have 
a specific set of diagnostic criteria.  The depressive disorders recognized by the DSM-5 
include major depressive episode/disorder, dysthymic disorder, bipolar episode/disorder, 
substance-induced mood disorder, mood disorder due to a general condition, adjustment 
disorder with depressed mood, and other psychiatric conditions in which depression can 
be a primary symptom (post-traumatic stress disorder, anxiety disorders, schizoaffective 
disorder, schizophrenia, and personality disorders) (American Psychiatric Association, 




Major depressive disorder is associated with ICD-10 codes F32.x and F33.x (U.S. 
Department of Health and Human Services, Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Treatment, 2013).  To have a diagnosis of 
major depressive disorder, five or more symptoms must be present for a two week period 
that cannot be attributed to another medical condition.  One, of the symptoms must be 
either depressed mood or loss of interest or pleasure, and it must reflect a change from 
previous functioning (U.S. Department of Health and Human Services, Substance Abuse 
and Mental Health Services Administration, Center for Substance Abuse Treatment, 
2013).  Listed below are the nine diagnostic symptoms that must be present for most of 
the day and nearly every day: 
1. Depressed mood  
2. Markedly diminished pleasure and interest in all or almost all activities  
3. Significant weight loss/gain without dieting or a decrease/increase in 
appetite 
4. Insomnia or hypersomnia  
5. Psychomotor agitation or retardation 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive/inappropriate guilt 
8. Diminished ability to think/concentrate or indecisiveness 
9. Recurrent thoughts of death, recurrent suicidal ideation without a plan, 




(U.S. Department of Health and Human Services, Substance Abuse and 
Mental Health Services Administration, Center for Substance Abuse 
Treatment, 2013) 
According to the U.S. Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, and the Center for Substance Abuse 
Treatment (2013), there are several other criteria that need to be met in order to establish 
a diagnosis of major depressive disorder.  The patient must be experiencing clinically 
significant impairment in social, occupational, or other areas of functioning.  The episode 
cannot be attributed to the effects of a substance or another medical condition.  Lastly, 
the depressive episode is not better explained by any diagnosis on the schizophrenia 
spectrum and there has never been a manic or hypomanic episode (U.S. Department of 
Health and Human Services, Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Treatment, 2013).   
Research studies have been conducted regarding the effects of depression on the 
overall health of the patient and the increased risk for disease such as risk for stroke, 
heart disease, and peptic ulcer disease.  A 2011 meta-analysis and systematic review on 
depression and the risk for stroke was completed by Pan, Sun, Okereke, Rexrode, and Hu 
(2011).  There were 28 prospective cohort studies chosen with a total of 317,540 
participants and 8,478 identified strokes (Pan et al., 2011).  The reviewers identified 
depression as being associated with a significant increased risk of stroke morbidity and 
mortality (Pan et al., 2011).  Another prospective cohort study of 63,469 women without 
baseline coronary heart disease was completed during 1992-2000 via the Nurses’ Health 




were at an increased risk for fatal coronary heart disease and sudden cardiac death, 
specifically if they were using antidepressants (Whang et al., 2009).  A population-based 
study completed in Taiwan analyzed data from a depression group (23,536 people) and a 
control group of similar age and gender (47,069) to assess for the risk of developing 
peptic ulcer disease (Hsu et al., 2015).  The depression group had a twofold higher risk of 
developing peptic ulcer disease when compared to the control group (Hsu et al., 2015).  It 
was noted that the depression group had an increased number of comorbidities that may 
affect peptic ulcer disease such as smoking and alcohol use (Hsu et al., 2015).  The study 
suggested that the depressed, aging, female patients with comorbidities should be closely 
monitored for peptic ulcer disease (Hsu et al., 2015).  These studies indicate that there are 
many different effects depression can have on the overall health of a patient. 
 The effects of depression stretch far beyond the physical and psychological 
symptoms that the patient may experience.  There are financial effects of depression that 
are felt within family units, the community, and the workplace.  The financial impact in 
the workplace stems from absenteeism and a reduction in productivity (Greenberg, 
Fournier, Sisitsky, Pike, & Kessler, 2015).  When considering the financial effects of 
depression, the costs associated with other comorbidity conditions also need to be taken 
into consideration.   
The economic burden of depression and comorbid conditions was estimated to be 
$210.5 billion in 2010 (Greenberg et al., 2015).  Out of that $210.5 billion the percentage 
breakdown is as follows: costs related to suicide (5%), workplace costs (48-50%), and 
direct costs (45-47%) (Greenberg et al., 2015).  The cost solely related to depression was 




2015).  When viewing depression as a whole picture, it is important to treat the 
depression in the most effective way possible in order to alleviate symptoms, decrease the 
potential for comorbid conditions, and limit the financial impacts that come from 
depression. 
Depression Screening and the PHQ-9 Questionnaire 
 Before treatment for depression can occur, a clinical diagnosis needs to be made.  
In family practice, a depression screening tool can be implemented to screen all adults for 
depressive symptoms.  The U.S. Preventive Services Task Force recommends screening 
for depression in the general adult population, including pregnant and postpartum women 
(Siu & USPSTF, 2016).  It was found that screening for depression with appropriate 
support systems in place improved clinical outcomes (Siu & USPSTF, 2016).  The 
USPSTF notes that an appropriate support system is one that is able to ensure patients are 
screened, diagnosed per screening results, and finally either treated for positive results or 
offered appropriate referrals (Siu & USPSTF, 2016).   
There are a number of screening tests or tools available for use. The primary care 
clinic setting for this scholarly project began using the PHQ-9 in 2017 to screen patients 
for depression.  As a commonly used instrument for depression screening, the Patient 
Health Questionnaire (PHQ) is considered a valid and reliable tool (Siu & USPSTF, 
2016).  The PHQ was derived initially from the PRIME-MD (Primary Care Evaluation of 
Mental Disorders) which is another diagnostic tool.  PRIME-MD is a one page 
questionnaire with 26 yes or no answers (Tamburrino, Lynch, Nagel, & Smith, 2009).  
PRIME-MD is used an initial screening for five general mental disorders: depression, 




Patient Health Questionnaire Primary Care Study Group, 1999).  Using the PRIME-MD 
diagnostic instrument as a starting point, the PHQ was formed as a self-administered, 
three page, depression screening tool (Kroenke et al., 2001). The PHQ was further 
condensed into the PHQ-9 consisting of nine questions focusing on the nine DSM-IV 
criteria for depression (Kroenke et al., 2001).   
Listed below are the nine questions that make up the PHQ-9 depression screening 
tool with the preceding statement of: “Over the last two weeks, how often have you been 
bothered by any of the following problems?”   
1. Little interest or pleasure in doing things 
2. Feeling down, depressed, or hopeless 
3. Trouble falling or staying asleep, or sleeping too much 
4. Feeling tired or having little energy 
5. Poor appetite or overeating 
6. Feeling bad about yourself, or that you are a failure or have let yourself or your 
family down 
7.  Trouble concentrating on things, such as reading the newspaper or watching 
television 
8. Moving or speaking so slowly that other people could have noticed.  Or the 
opposite, being so fidgety or restless that you have been moving around a lot 
more than usual 
9. Thought that you would be better off dead, or of hurting yourself 
Patients are asked to check precoded boxes that indicate on a scale of 0-3 whether 




zero), several days (score of one), more than half the days (score of two), or nearly every 
day (score of three).  Patient scores can range from 0-27 with the ranges correlating to 
five different levels of depression (minimal, mild, moderate, moderately severe, or severe 
depression).  There is a final unscored question added to the end that asks, “How difficult 
have these problems made it for you to do your work, take care of things at home, or get 
along with people?”  For that question, the patient is able to check one of the following 
statements: Not difficult at all, somewhat difficult, very difficult, or extremely difficult. 
Evaluation of the PHQ-9 indicates that it is a reliable and valid clinical tool.  The 
internal reliability of the PHQ-9 had a Cronbach’s α of 0.89 in primary care studies with 
an excellent test-retest reliability (Kroenke et al., 2001).  The PHQ-9 was found to 
discriminate well between persons with and without major depression with a ROC 
analysis showing the area under the curve to be 0.95 (Kroenke et al., 2001).  Based on the 
statistical and clinical findings, the PHQ-9 can be utilized as a valuable tool for 
depression screening in the adult primary care setting.  A study completed with 566 
participants compared the Center for Epidemiologic Studies Depression Scale (CES-D) 
and the PHQ-9 (Milette et al., 2010).  Despite both tools having similar reliability and 
validity, the PHQ-9 was the overall preferred tool for being shorter in length, easily 
administered, and simple to score (Milette et al., 2010). 
The Family Nurse Practitioner Role in Treating Depression 
In many rural areas, mental health providers are a very limited resource.  When 
considering the vast amount of people that may require treatment for a mental health 
condition, other providers are required to step in and provide treatment.  The lack of 




primary care provider (PCP), and in many cases the PCP may be a family nurse 
practitioner (FNP).  The FNP role in depression management consists of screening for 
depression, providing medical treatment for depression, and referring out to specialty 
services if required.  A small study of 44 nurse practitioners discovered that they reported 
one-third of the patients they see in a weeks’ time are reporting mental health problems 
(Shell, 2001).  Within the rural county that this project took place in, there are less than 
ten certified medical providers for mental health.  There are numerous licensed 
counselors and therapists for adjunctive therapies, but they are unable to provide any 
prescriptions for required medications.  Medication management mostly falls on the 
primary care providers in the area due to the limited resources available.  A study 
completed in 2001 of 44 nurse practitioners indicated that 71% felt they were adequately 
informed to be prescribing antidepressants, 56% indicated that they needed additional 
education regarding antidepressant prescribing, and 86% stated they would attended a 
continuing education class on antidepressants (Shell, 2001). 
There are different types of treatment that can be utilized for the treatment of 
depression.  These treatments include cognitive behavioral therapy and prescribed 
medications.  The FNP has to consider many different factors when prescribing an 
antidepressant medication.  The factors considered when treating depression include cost 
of the medication, possible drug interactions, potential side effects, and other medical 
conditions that the patient may have been diagnosed with (Shell, 2001).  Based on these 
factors, a medication may be selected from one of the antidepressant medication classes.  




most commonly prescribed SSRIs and SNRIs for the treatment of depressive conditions 
(Burman et al., 2015). 
Medication Prescribing Practices 
 Primary care providers, such as family nurse practitioners, are able to treat 
depressive disorders with a variety of medications.  The classes of antidepressant 
medications are selective serotonin reuptake inhibitors (SSRIs), serotonin non-reuptake 
inhibitors (SNRIs), tricyclic antidepressants (TCAs), and atypical antidepressants 
(Uphold & Graham, 2013).  Another class of antidepressants that are no longer widely 
utilized due to side-effect profiles and food/medication interactions are a group called 
monoamine oxidase inhibitors (MAOIs) (Hirsch & Birnbaum, 2018).  This medication 
class may still be utilized for treatment resistant depression, but they are considered third 
or fourth line treatment options (Hirsch & Birnbaum, 2018).   
The best tolerated medication class are the SSRIs which are considered the first 
line treatment for depression (Uphold & Graham, 2013).  A few examples of SSRIs are 
citalopram, fluoxetine, and sertraline.  Generally, these medications are effective at low 
dosages and don’t require frequent dosage changes (Uphold & Graham, 2013).  The 
evidence does not support that one SSRI is going to be more effective than the other, 
however, it is important to consider potential drug interactions when deciding on a 
medication (Uphold & Graham, 2013).   
SNRI’s are a class of antidepressants that may provide an added benefit to 
patients that also have a coexisting pain condition such as neuropathic pain (Uphold & 
Graham, 2013).  These medications may not be as tolerated as well as SSRIs in older 




desvenlafaxine (Uphold & Graham, 2013).  The atypical or “other” antidepressants 
include bupropion and mirtazapine and have been noted to be relatively safe when it 
comes to overdose concerns (Uphold & Graham, 2013).  TCAs have been found to be the 
class that causes the most side effects that may result in patient noncompliance and 
should only be prescribed to patients who have failed treatment from the other classes 
(Uphold & Graham, 2013).  
With all medication classes, there are general standards on initiation, monitoring, 
and dosage titration.  Uphold and Graham (2013) offer the following prescribing 
guidelines for antidepressants: 
1. The initial antidepressant medication should be selected based on patient 
symptoms, needs of the patient, and the side effect profile. 
2. Initiate the chosen medication at half the recommended dose and titrate up 
slowly over two weeks. 
3. Schedule the patient for a follow-up appointment four weeks after 
medication initiation to assess compliance and symptom improvement. 
4. If symptoms have begun to decrease but are not at an optimal level, 
consider increasing the dosage with another follow-up appointment 
scheduled for four weeks after the change. 
5. If after 12 weeks of treatment, the patient does not have a substantial 
benefit from the medication; or the side effects are unbearable, the 
medication should be switched to an alternative medication. 
Once an optimal medication regimen has been achieved, the patient should follow 




(Uphold & Graham, 2013).  It is the recommendation that the patient stay on the 
successful medication for at least six months to prevent symptom relapse (Uphold & 
Graham, 2013).  If the patient has had more than two previous episodes of depression, 
they are considered high risk of relapse and should stay on the prescribed medication for 
at least two years (Uphold & Graham, 2013).   
Following the guidelines for antidepressant medication selection have been the 
go-to practice for primary care providers.  However, with the increase in 
pharmacogenomic testing, primary care providers are now able to provide the patient 
with a personalized list of medications that will work with their genetic makeup and 
metabolism. 
Personalized Medicine and Pharmacogenomic Testing 
 There are many different factors to consider when deciding what medication to 
prescribe a patient.  The patients age, gender, renal function, hepatic function, substance 
use, and genetic factors are a few of the many variables to take into consideration with 
each and every patient (Hall-Flavin, Schneekloth, & Allen, 2010).  The time frame for an 
optimal therapeutic response in antidepressant medications may take up to 12 weeks’ 
time (Hall-Flavin et al., 2010).  Personalized medicine can be defined as, “The use of 
genotypic information to stratify disease and select a therapy that is particularly suited to 
an individual patient…” (Hall-Flavin et al., 2010, p. 40).  With the use of 
pharmacogenomic testing, there is the potential for a decrease in medication side effects 
and a decrease in overall time spent trying different medications that may not be 




 Pharmacogenomic testing detects genetic variations that are coded for proteins, 
specifically, drug-metabolizing enzymes (Hall-Flavin et al., 2010).  The specific test 
utilized at the clinical site used for this project is the GeneSight® Psychotropic 
pharmacogenomic test which analyzes how multiple genes metabolize medications.  The 
genetic sample is retrieved via a buccal mucosal swab and is sent to an outside lab for 
processing with results coming within 36 hours of the appointed GeneSight® lab 
receiving the sample (GeneSight, 2018).  The GeneSight® Psychotropic test analyzes 12 
different genes to assess how they influence the patient’s response to many psychotropic 
medications (GeneSight, 2018).  The pharmacokinetic genes that are tested in the 
GeneSight® test are the cytochrome P450 (CYP) enzymes;, CYP1A2, CYP2B6, 
CYP2C19, CYP2C9, CYP3A4, and CYP2D6, and also UGT1A4 and UGT2B15 
(GeneSight, 2018).  The test also identifies SLC6A4 which is a serotonin transporter, and 
HTR2A which is a serotonin receptor (Altar et al., 2015).  There are also two other 
pharmacodynamic genes, HLA-B*1502 and HLA-A*3101, that are associated with a 
higher risk for dermatologic and hypersensitivity reactions (GeneSight, 2018).   
The pharmacogenomic testing may show that a patient has an altered P450 
enzyme which causes certain medications to either be metabolized poorly or ultrarapidly 
(Altar et al., 2015).  The differences in medication metabolism corresponds with the 
recommendation GeneSight® gives for medication dosing. For example a patient with 
poor metabolism may require a lower dosage versus a patient identified as being a 
ultrarapid metabolizer needing a higher medication dosage (Altar et al., 2015).  This 




medications are in the use as directed group (green), moderate gene-drug interaction 
group (yellow), or significant gene-drug interaction group (red) (Altar et al., 2015).   
Along with placing the medications into the appropriate groups, GeneSight® also 
provides supplemental information on why each medication is in that class.  For a 
medication that was placed in either the yellow or red groups, there are numbers that 
correspond to footnotes explaining the rationale.  For example, an explanation might 
indicate that for a specific individual, an antidepressant medication, such as citalopram, 
creates too high of a serum level at a normal dose and therefore, a lower dose is required 
(Altar et al., 2015).  Another example would be the test identifying that an individual is at 
an increased risk of side effects when taking a certain medication or that the FDA labels 
this medication as contraindicated for this genotype (Altar et al., 2015).  
The information discussed above is computed into an individualized medication 
list that indicates the best medication choices based on the patients’ genetic make-up.  
The report is available online to the providers office within 36 hours.  This personalized 
report allows the FNP to review all the medications, what group the medication was 
placed in, and then make an educated decision regarding what antidepressant to prescribe. 
Application of Testing in Primary Care 
 Depression is a common mental disorder with over 300 million people affected 
worldwide and is the leading cause of disability across the world (World Health 
Organization, 2018).  A large clinical trial of 4,041 outpatients with depression found that 
after each medication failure there was an increase in intolerance to the treatment plan 
which subsequently increased again after each failed medication (Warden, Rush, Trivedi, 




care setting, this intolerance and medication failure has the potential to be decreased.  
Personalized medication in primary care aims to increase medication tolerability, 
improve treatment outcomes, and increase patient adherence to the prescribed 
medications (Altar et al., 2015). 
 A study completed by J. Winner, Allen, Altar, and Spahic-Mihajlovic (2013) 
found that nine of their 97 study participants were on a medication that was in the red 
group on the GeneSight® test.  Those nine participants had 69% more healthcare visits 
and more medical absence days than the participants with medications in the green or 
yellow group.  It was also discovered during data analysis that the longer the participant 
was on a red group medication, the more healthcare visits they had (J. Winner et al., 
2013).   
A one year study analyzed 2,168 patients that underwent GeneSight® testing 
along with a control group of 10,880 patients (J. G. Winner et al., 2015).  Their study 
showed that the GeneSight® test group patients saved over $1,000 in medication costs 
with an average cost saving of $2,774.53 when the patient switched to a medication 
deemed best based on GeneSight® test results (J. G. Winner et al., 2015).   
 Another notable study was a 10-week long prospective double-blind randomized 
control trial on the clinical impact of pharmacogenomic testing (J.G. Winner, Carhart, 
Altar, Allen, & Dechairo, 2013).  There were 51 patients that participated in this study 
and they had a clinical diagnosis of major depressive disorder.  It is important to note that 
this study did exclude patients with a diagnosis of bipolar disorder (any type), 
schizophrenia, schizoaffective disorders, and an active substance abuse or dependence.  




were randomly chosen for the GeneSight® testing group.  Assessment data were 
collected at baseline, four weeks, six weeks, and ten weeks using a variety of tools, 
including the PHQ-9 Patient Health Questionnaire.  During the 10-week study, 
physicians adjusted medications in the GeneSight® testing group and the TAU group at 
about the same rate (53% test group and 58% control group).  Notably, 100% (seven 
total) of patients that were in the GeneSight® testing group and were on a red group 
medication were changed from that medication.  Mean PHQ-9 scores in the GeneSight® 
test group improved by 35.4% versus the TAU group only improved by 21.3% (J. G. 
Winner et al., 2013). 
 Hall-Flavin et al. (2013) completed an open-label study with an unguided and 
guided group that utilized GeneSight® testing to assess the benefit for treatment of major 
depression.  There were 233 study participants with a diagnosis of major depressive 
disorder or depressive disorder NOS between the ages of 18 and 72 that were included in 
the study.  Exclusions for this study included bipolar type 1, schizophrenia, and 
schizoaffective disorder; inclusion criteria included a minimum score of 14 on the 17-
item Hamilton Rating Scale for Depression (HAMD-17).  After all exclusions were 
applied, there were 227 participants eligible for the study, 113 were placed in the 
unguided group and 114 in the guided group.  Both groups received GeneSight® testing 
but the results were withheld from the unguided group until the study completion.  
Assessment data were collected at baseline, two weeks, four weeks and eight weeks 
including a HAMD-17, the Quick Inventory of Depression Symptomatology – Clinician 
Rated (QIDS-C16), and a PHQ-9.  The guided group had more improvement on the 




group.  The unguided group participants that were prescribed a medication that was not 
compatible with their genotype experienced the least improvement; while the guided 
group participants with incompatible medications showed the greatest improvement over 
the eight-week study.  There was a 40.1% decrease in PHQ-9 scores in the guided group 
versus only a 19.5% decrease in the unguided group.  The participants in the guided 
group had a 26.4% remission rate versus a 12.9% remission rate in the unguided group 
based on the QIDS-C16 scores (Hall-Flavin et al., 2013). 
The information given on the GeneSight® Psychotropic test results are used as a 
guide to the patients personalized treatment.  The test is a tool that the provider should 
utilize along with direct patient conversations to choose an appropriate medication.  The 
medication the provider and patient chose may be in the green or yellow group.  If the 
chosen medication is in the yellow group, it is important for the provider to read the 
footnotes and take into consideration what the gene-drug interaction is and make 
appropriate adjustments to the medication dosage. 
Patient Views on Personalized Medicine 
 The current research on patient perspectives regarding genetic testing for 
medication selection is limited, but the findings available are pertinent to the prescribing 
practices of the family nurse practitioner.  A study by Haga et al. (2016) completed 
baseline surveys prior to pharmacogenetic testing and a follow up survey three months 
after testing.  The patients in this study completed pharmacogenetic testing for a variety 
of medications, not specifically for antidepressants.  There were 63 total patients 
underwent the testing process with only 17 completing the baseline survey and 12 of the 




the patients decision to undergo genetic testing were that their provider recommended the 
testing (59%), that patients understood the testing would allow the primary care provider 
to select the best medication for them (76%), and that there was a perceived value of the 
testing to optimize their treatment (65%).  83% of patients believed that the testing was 
helpful to their provider in regard to their treatment plan, but only 58% had increased 
confidence with the medication that was prescribed in comparison to past prescribed 
medications.  On the follow-up survey, all patients stated they would be very or 
somewhat likely to undergo pharmacogenetic testing for other medications if it was 
indicated (Haga et al., 2016).   
 A participant in a study completed by Trinidad et al. (2015) provided the 
following quote regarding the use of pharmacogenetic testing in the treatment of her 
depression:  
Even if it takes six months [to get pharmacogenetic test results], I have had --- 
looking back, it’s like, you know, gee, do you think that particular drug was what 
took like four years out of my life? Yeah. If somebody could go in there and 
figure it out in four months, yeah, that would be better. (p. 23) 
Another pertinent patient quote compared testing to riding on a bus, “You could 
jump off anywhere downtown and get to a store, but you want to get off closer to the 
store you’re going to” (Trinidad et al., 2015, p. 23).  The above statements further support 
the use of pharmacogenetic testing for appropriate and personalized medication selection.  
However, some of the study participants felt that the providers may end up relying too 
much on the test results and could potentially not give appropriate consideration to other 




These findings support that patients find the testing to be useful and pertinent to 
their overall treatment plan when utilized appropriately by their provider.  In the family 
practice setting, it is important to continue to discuss treatment options with the patient 
and take their views about pharmacogenetic testing into consideration when ordering said 
test.  The health belief model may help guide the process of relaying the potential 
perceived benefit of pharmacogenetic testing to patients. 
Theoretical Framework 
 The health belief model was originally established in 1950 by three social 
psychologists that were working for the U.S. Public Health Services to try and improve 
the use of preventative services (Rosenstock, 1974).  Health behaviors were explained in 
the health belief model by using the following concepts: perceived susceptibility of the 
health problem, perceived severity, perceived benefits, perceived barriers, and cues to 
action (Castonguay et al., 2016).  Rosenstock added a sixth concept to his model in 1988 
called self-efficacy (Garner, 2014).   
The perceived susceptibility of the health problem is the patients opinion on their 
chances of getting a condition (Garner, 2014).  When faced with a diagnosis of 
depression, the patient may perceive that they never would be depressed or be diagnosed 
with depression.  How serious the patient believes the condition is and what its 
consequences will be is known as the perceived severity (Garner, 2014).  A patient 
diagnosed with depression for the first time may perceive the severity of the diagnosis to 
be low; however, a patient that has been diagnosed previously with depression may view 
this as more severe.  The perceived benefits in the health belief model are how the patient 




This would correlate to a patient being prescribed medications, cognitive behavioral 
therapy, or pharmacogenomic testing and what he or she believes regarding the benefits 
from those actions.   
On the opposite end of the spectrum, perceived barriers are the patients opinion 
on the potential barriers to treatment (Garner, 2014).  Barriers could range from monetary 
concerns of the medications, therapy, or potential cost of the pharmacogenomic testing to 
the patients perceived social stigma of being diagnosed with a depressive condition.  
Cues to action are the patients readiness to act and begin overt behaviors while self-
efficacy is the confidence to perform an action (Garner, 2014).  Cues to action would 
include the positive acts of taking the prescribed medication, completing the 
pharmacogenomic testing, or going to a therapy appointment.  Self-efficacy with a 
diagnosis of depression could correspond to reading self-help books, exercising, or 
engaging in other self-care measures that demonstrate a belief that a change in health 
behavior can positively influence health (Garner, 2014).  This is the belief that a change 
in health behaviors can positively influence health (Garner, 2014). 
Pharmacogenomic testing for psychotropic medications is one way to provide a 
personalized treatment plan for patients with depression.  The health belief model 
demonstrates how the perceived benefit of testing will potentially allow for successful 
treatment based on genetic make-up and metabolism.  By utilizing the health belief model 
and pharmacogenomic testing, primary care providers could potentially prevent treatment 







This scholarly project seeks to understand how GeneSight® testing effects the 
prescribing practices of a nurse practitioner in a rural Michigan clinic and how/if it has 
any change on the patients PHQ-9 scores at scheduled follow up appointments.  The 
literature supports the use of psychotropic pharmacogenomic testing to help guide the 
provider in their medication selection process.  The studies have shown that the patients 
in the guided, or the pharmacogenomic testing group, have significant decreases in their 
PHQ-9 depression screening scores.  Based upon the review of literature, the scholarly 







Purpose, Sample, and Recruitment 
 The purpose of this project was to assess if medication changes based on 
GeneSight® Psychotropic pharmacogenomic testing resulted in improvement of PHQ-9 
depression screening scores.  The GeneSight® Psychotropic pharmacogenomic testing 
was implemented at the clinical site under study prior to project implementation in 
February 2018.  The clinical site can be described as a small, family practice clinic 
located in a rural area.  The clinical site currently cares for 1,972 adult patients between 
their primary care and walk-in clinic.  The testing is currently being utilized at the family 
nurse practitioner’s discretion for patients who have had recurrent failed treatment on one 
or more medications that are FDA approved to treat depression. 
 The inclusion criteria for the project required control and test group patients to be 
between the ages of 18-99 years old with a diagnosis of depression that had received 
treatment from the primary care provider (family nurse practitioner).  The control group 
inclusion criteria also included being seen by the provider within the three months prior 
to GeneSight® testing implementation.  The test group inclusion criteria required that 
they received GeneSight® testing at the clinical site within three months after testing 
implementation.  The exclusion criteria for both the control and test group included being 
under the age of 18 and not having a current diagnosis of depression.  Patients were 
excluded from the test group if they did not receive the GeneSight® testing during the 
specified time frame.  The sample size was deemed to be 23 which is the total number of 
patients seen during the three months prior to testing implementation and the three 




http://www.raosoft.com/samplesize.html, was used with a confidence level of 95% with a 
5% margin of error.   The recommended sample size was 22 patients.   
There was no recruitment process for the participants of this study.  The patients 
primary care provider, independently of this project, chose the participants for 
GeneSight® Testing based on their patient assessment and past history of depression 
treatment.  Medical necessity for GeneSight® Testing was determined by the provider 
and required treatment failure on at least one psychotropic medication that is FDA 
approved to treat depression. 
Scholarly Project Approval 
 A member from Northern Michigan University Institutional Review Board (IRB) 
reviewed an IRB proposal and confirmed that IRB approval was not required (see 
Appendix A).  The nature of this project falls under a quality review project as it is a 
retroactive chart review. 
Design and Measures 
 This DNP scholarly project utilized a quantitative and a nonequivalent control 
group research design (Terry, 2015).  Retroactive chart reviews were completed for ten 
patients that were treated for depression in the three months prior to the implementation 
of GeneSight® Testing as a non-randomized control group.  All patients who received 
GeneSight® Testing for treatment resistant depression in the three months after 
implementation were considered part of the test group and also received a retroactive 
chart review.   
The information retrieved from the charts were deidentified at the point of 




diagnosis code, PHQ-9 scores, medication lists, stated medication side effects, time 
between visits for depression, other medical diagnoses, what GeneSight® medication 
grouping type (green, yellow, red) the medications were in for the test group, the number 
of visits they were seen and treated for depression, and all FDA approved antidepressant 
medications that had been prescribed. 
Informed Consent, Risks and Benefits 
 This scholarly project was reviewed by a university IRB board member and was 
deemed exempt from needing informed consent.  All information was deidentified and 
retrieved via retroactive chart review as a quality measure.  Overall, this research project 
posed a minimal risk to all parties involved.  The potential risks associated with this 
project were limited to psychological risk factors of the patients.  There are no known 
physical, economic, or legal risks associated with this study.  The psychological risks 
were very low as all identifying data were removed at the point of data collection.   
This study aimed to benefit both the patient and the provider.  The benefit for the 
patient may include a better medication selection based on the GeneSight® Test results 
and a potential decrease in PHQ-9 scores.  The provider may benefit from a patient 
specific medication list to choose from and a decrease in office visits for depression. 
Instrument 
 The PHQ-9 depression screening tool (see Appendix C) was already being 
utilized at the clinical site for routine depression screening.  It is a reliable and validated 
depression screening tool that is comprised of nine questions and is completed by the 
patient prior to office visits.  The questions are asked based on the statement of, “Over 




problems?”.  Listed below are the nine questions that are asked on the PHQ-9 patient 
questionnaire: 
1. Little interest or pleasure in doing things 
2. Feeling down, depressed, or hopeless 
3. Trouble falling or staying asleep, or sleeping too much 
4. Feeling tired or having little energy 
5. Poor appetite or overeating 
6. Feeling bad about yourself, or that you are a failure or have let yourself or 
your family down 
7. Trouble concentrating on things, such as reading the newspaper or 
watching television 
8. Moving or speaking so slowly that other people could have noticed.  Or 
the opposite, being so fidgety or restless that you have been moving 
around a lot more than usual 
9. Thought that you would be better off dead, or of hurting yourself 
 The patient answers the questions by checking a box for one of the following 
statements:  Not at all (score of zero), several days (score of one), more than half the days 
(score of two), or nearly every day (score of three).  These scores are then added up to a 








Table 1  
Depression Severity Based on Total PHQ-9 Scores 
Total Score Depression Severity 
1-4 Minimal depression 
5-9 Mild depression 
10-14 Moderate depression 
15-19 Moderately severe depression 
20-27 Severe Depression 
 
Research Questions 
 This DNP scholarly project aimed to answer the following questions: 
1. As compared to a control group, what effect, if any, does utilizing GeneSight® 
Psychotropic pharmacogenomic testing have on prescribing patterns of primary 
care providers? 
Hypothesis:  Primary care providers will choose medications based off the 
personalized medication list that are in the green (use as directed) category. 
2. What effect, if any, did medication changes as a result of GeneSight® 
Psychotropic pharmacogenomic testing have on PHQ-9 depression screening 
scores? 
Hypothesis:  Personalized psychotropic medication choices based on the 
GeneSight® test will result in a decrease in PHQ-9 scores within four to eight 






 Data were collected from the electronic medical record, deidentified, and entered 
into an Excel Spreadsheet.  The information collected included gender, race, age, ICD-10 
diagnosis code related to depression, PHQ-9 scores, medication lists, stated medication 
side effects, the total weeks between visits for depression, other medical diagnoses, what 
GeneSight® medication grouping type (green, yellow, red) the medications were in for 
the test group, the number of visits patients were seen and treated for depression, and all 
FDA approved antidepressant medications that had been prescribed.  IBM SPSS software 
application version 20.0 was used to analyze the collected data.  The deidentified data 
will be kept in a locked drawer for the next seven years.  Results are discussed in depth in 







This doctoral scholarly project aimed to evaluate if GeneSight® testing had any 
effect on prescriber patterns/practices and patient reported PHQ-9 depression screening 
scores.  The Chapter Two literature review supports the use of GeneSight® testing in 
primary care settings for patients that have experienced treatment failure.  The rural 
clinical site for this project implemented the PHQ-9 depression screening tool in 2017.  
The GeneSight® Psychotropic pharmacogenomic testing was implemented and was 
utilized on a small number of patients that were considered to have had treatment failure 
on at least one antidepressant medication.  The PHQ-9 is a valid and reliable tool for 
depression screening that is self-administered by the patient.  A retroactive chart review 
was completed during the time period of three months before GeneSight® Psychotropic 
pharmacogenomic testing was implemented and three months after implementation. 
Post-Data Collection Practitioner Discussion 
An informal discussion was completed post-data collection with the FNP of the 
rural clinic associated with this doctoral scholarly project.  The following topics were 
discussed with the FNP:  
1. Readiness to treat depression 
2. PHQ-9 screening tool useful for identifying/treating depression 
3. GeneSight® testing usefulness for prescribing practices 
4. Patient or provider barriers to ordering the test 





Themes from the interview with the family nurse practitioner discussion regarding 
her readiness to treat depression included: 1. Immediately post-graduation, she felt best 
equipped to prescribe SSRI antidepressants only; 2. Knowledge of antidepressants was 
only ascertained from formal pharmacology classes in school; 3. SSRIs were initially the 
main class of antidepressants used in her practice; however she has expanded her 
knowledge and comfort level with prescribing other antidepressant classes; and 4. Further 
education has to be sought out post-graduation through medical conferences dealing with 
the topics of depression and anxiety. 
In terms of using the PHQ-9 screening tool, the provider shared that it was 
implemented at the clinical site in 2017.  She has found that it is a useful tool for 
recognizing, diagnosing, and treating depression.  However, she discovered that the 
PHQ-9 score sometimes does not correlate well with the patient’s overall perception of 
their depression symptoms.  It has been noticed that even though patients may score high 
on the PHQ-9,  they may still be happy with their overall progress and not want to make 
any changes to their medication regimen.   
Finally, the usefulness of GeneSight testing, potential barriers for testing, and 
financial implications were discussed.  Currently, the provider has not found that the 
GeneSight® testing has made a significant impact on her prescribing practices for 
treating depression.  However, it was acknowledged that it has only been used on a small 
number of patients since implementation.  The patients that have utilized the GeneSight® 
testing have been excited about what it means for their treatment plan.  She stated that the 
test has been utilized when the patient has had treatment failure on multiple 




still be in the green, use as directed, column.  With multiple medications in the green 
column, the provider has found that some trial and error may still be required to find the 
best medication for the patient despite the fact that in theory, the GeneSight® testing 
should reduce the number of medications that the patient must try.  This would be true 
only if the test results show medications in the yellow or red group.  Overall, the provider 
feels that the testing should decrease costs for the patient due to savings on potential 
multiple medication and visit copays.  
Data Analysis 
The data for this analysis came from a convenience sample through retroactive 
chart reviews for both the control and the test group.  The control group chart review 
revealed n = ≤10 and the test group chart review also was n = ≤10.  Due to the small 
sample size, all data will be presented in percentages.  The exact n values for the control 
and test group will be omitted.  This process assists in protecting the study participants 
from potentially being identified.  All data were processed via the IBM SPSS software 
application version 20.0.  Both descriptive and inferential methods were utilized for the 
statistical analysis.  Categorical variables are presented using frequency distribution.  
Interval scale variables, such as age and PHQ-9 scores, are summarized using means and 
standard deviations.  Matching of distribution of age between control and test groups was 
completed using independent samples t-test.  A comparison of the total number of visits 
for depression in the control and test group patients was completed by using independent 
samples t-test.   Comparison of PHQ-9 scores across the two measurement periods during 
the study period was completed by using a paired t-test.  All statistical tests were 





 The majority of the control group participants were female (70%), the remaining 
participants were male (30%) (See Figure 1).  In the test group, 100% of the participants 
were female.  100% of the patients in the control and test group identified their race as 
Caucasian.  The mean age of patients in the control group was M = 38.20 (SD = 16.86).  
The mean age of patients in the test group was M = 56.50 (SD = 23.35).  Results of 
independent samples t-test indicated that there is no significant difference in mean age of 
patients between the control group and test group (t (≤10) = 1.341, p = .209).   
 
 
Figure 1. Pie chart of gender of patients in the control group 
 
The patients in the control group had varying ICD-10 diagnosis codes that 
included F33.0 (Major Depressive Disorder, Recurrent, Mild), F33.1 (Major Depressive 










Moderate) (See Figure 2).  100% of the patients in the test group had an ICD-10 
diagnosis code of F33.1 (Major Depressive Disorder, Recurrent, Moderate). 
 
Figure 2. Pie chart of control group ICD-10 Codes 
A paired t-test was used to compare the PHQ-9 scores across the two 
measurement periods during the study period.  Table 2 below presents descriptive 
statistics of PHQ-9 scores for the control group along with summary of results of paired 
t-test.  The mean PHQ-9 score during the first measurement period was M = 7.00 (SD = 
4.243) which is mild depression.  The mean PHQ-9 score during the second measurement 
















Comparing control group PHQ-9 scores between two measurement periods 
Measurement Mean n SD t p 
Period 1 7.00 ≤10 4.243 1.40 .395 
Period 2 3.50 ≤10 .707   
 
 Results of paired t-test indicated that the null hypothesis of no significant 
difference in the mean PHQ-9 scores cannot be rejected at .05 level of significance (t 
(≤10) = 1.40, p = .395).  This indicates that in the control group there was no significant 
difference in PHQ-9 score distribution between the two measurement periods.  In the test 
group, there was only one pair of PHQ-9 scores recorded.  Therefore, no statistical test 
could be performed on the test group PHQ-9 scores.  For the recorded pair of PHQ-9 
scores, the PHQ-9 score was 24 in the first measurement period and subsequently 
dropped to 9 during the second measurement period.  This is a potential indication that 
GeneSight® intervention caused a reduction in PHQ-9 scores during the study period.  
However, there must be a bigger representative sample size to generalize the results with 
statistical support.  
 The antidepressants prescribed in the control group were changed for 50% of the 
patients between the two appointments.  In the control group, 30% had dosage increases, 
10% had a dosage decrease, and 10% discontinued the medication.  20% of the control 
group patients had no medication changes and the last 30% did not have any follow-up 
appointments on record.  The majority of the patients were taking an SSRI (80%) and the 
rest of the control group patients were taking an SNRI (20%).  See Table 3 for a 




the control group were prescribed alprazolam for anxiety and 20% were prescribed 
trazodone for insomnia.  
Table 3 
Control group medication class breakdown 
Medication Drug Class Percentage  
Escitalopram SSRI  30%  
Citalopram SSRI 30%  
Paroxetine SSRI 10%  
Fluoxetine SSRI 10%  
Venlafaxine SNRI 20%  
 
After GeneSight® test results were received, 50% of the patients in the test group 
had subsequent medication changes.  Any medication that was listed in the red category 
on the GeneSight® test was discontinued in 100% of the test group patients.  Table 4 lists 
the medications and the drug classes that the patients were on before and/or after the 
GeneSight® testing was completed.  Unlike the control group, the medications utilized 
for the patients in the test group were from a wider variety of classes.  This could be 
attributed to previous treatment failure on the first line medications that were being 
utilized in the control group patients.  It is important to note that the test group patients 










Test group medication class breakdown 
Medication Drug Class Percentage  
Buproprion HCL NDRI 50%  
Trazodone SARI 100%  
Citalopram SSRI 50%  
Desvenlafaxine SNRI 50%  
Quetiapine Atypical 50%  
 
 In the control group, the time between a medication/dosage change and their 
follow-up appointment ranged between 2.5 weeks to 18 weeks with a mean of 6.86 weeks 
(SD = 5.178).  In the test group, the time between a medication/dosage change and their 
follow-up appointment ranged between 4 weeks to 8 weeks with an average of 6 weeks 
(SD = 2.828).  Results of independent samples t-test indicated that there was no 
significant difference (see Table 5) in the mean weeks’ time between medication/dosage 
changes and their follow-up appointments between the control and the test groups (t 
(≤10) = .218, p = .834).  
Table 5 
Time gap between medication change or appointments between control and test groups 
Group Mean n SD t p 
Control  6.86 ≤10 5.178 .218 .834 
Test 6.00 ≤10 2.828   
 
 Table 6 presents descriptive statistics for total number of visits made by patients 




times (SD = 2.044). In the test group, patients visited on an average 4.50 times (SD = 
2.121) for treatment of depression. Independent samples t-test is used to test the 
significance of the difference in mean number of visits made by patients in control and 
test group. Results of independent samples t-test indicates that null hypothesis of no 
significant difference in mean number of visits between control and treatment groups 
cannot be rejected at .05 level of significance (t (≤10) = 1.070, p = .310). It is concluded 
that there is no significant difference in average number of visits for depression between 
patients in control and treatment groups.  
Table 6 
Number of visits for treatment of depression 
Group n Mean SD t p 
Control  ≤10 2.80 2.044 1.070 .310 
Treatment ≤10 4.50 2.121   
 
There were a variety of other health conditions found in the control group (See 
Figure 3).  It is an interesting finding that a large percentage of control group patients had 
a concurrent diagnosis of anxiety which may have impacted the providers decision 
making process for medication selection.  The test group participants also had concurrent 
medical diagnoses of anxiety, insomnia, and vertigo (Figure 4).  In the control group, 
brain fogginess and sweating were reported as side effects to the prescribed 
antidepressants.  There were no side effects recorded in the providers note for patients in 






Figure 3. Control Group Medical Diagnoses 
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Strengths and Limitations 
 The most significant limitation of this project was the lack of test group 
participants and the lack of documented PHQ-9 scores for both the test and the control 
group.  As this project was a retroactive chart review, there was no opportunity for 
participant recruitment or for the researcher to intervene and make sure screening was 
completed or charted in the electronic medical record.  The time frame of the study is 
also a notable limitation.  Three months prior to testing implementation and three months 
post testing implementation was the timeline for this project.  A longer time frame would 
have allowed for a larger control group and a potentially larger test group.  The project 
design is also a limitation for that reason.  A different project design that included 
participant recruitment, monitored PHQ-9 screening at each visit, over a longer period of 
time would have been an ideal situation.   
 A strength of this project was that the intervention of the GeneSight® test had 
been studied in the past and was already been proven to have a significant impact on the 
treatment of depression.  Another strength is that the clinical site already had the PHQ-9 
in place as a validated and reliable tool for depression screening. Finally, the clinical site 
and practitioner were both willing and helpful with their time and access to the electronic 
medical records.  
Future Studies 
Future studies could benefit from utilizing a qualitative questionnaire for both the 
patient and the provider.  The qualitative data from patient experiences could include 
background on why they did or did not utilize the GeneSight® test, how they felt about 




the test results.  This information could help primary care providers understand what 
patients are thinking about the test, the testing process, and the test results.  Qualitative 
data from the providers perspective could potentially include their thoughts on when and 
why to order the GeneSight® test for patients.  Exploring the training and comfort level 
of practitioners in rural settings acting as the primary prescribers for symptomatic 
depression might also add insight to whether or not the practitioner feels that the 
GeneSight® testing is necessary for proper and effective patient care.  Future studies 
could also investigate what other nonpharmacological therapies the patients had tried 
prior to the GeneSight® testing and what role they may have played in their overall 
treatment plan. 
Future studies could also benefit from a cost analysis in a control group and test 
group to assess what financial effects GeneSight® testing may have on the overall costs 
associated with depression.  At the time of this study, patients have a maximum out of 
pocket cost of $330 for GeneSight® testing (GeneSight, 2018).  Many insurance 
companies are covering a portion or all of the cost of the test (GeneSight, 2018).  The 
cost analysis study could include individual patient costs for transportation to each office 
visit, insurance deductibles, office visit costs/copays, prescription co-pays, and even the 
cost of lost productivity hours.  In the case that the out of pocket GeneSight® testing cost 
is the maximum of $330, there is the potential for the patient to still have a large overall 
cost saving. 
Recommendations and Conclusions 
 While this scholarly project failed to have significant findings for the research 




PHQ-9 depression screening in primary care is sufficient to support the implementation at 
the clinical site (Altar et al., 2015; Hall-Flavin et al., 2013; J. Winner et al., 2013; J. G. 
Winner et al., 2013; J. G. Winner et al., 2015; Kroenke et al., 2001; Siu & USPSTF, 
2016).  Findings in this study support current prescribing guidelines, appointment follow-
up times, and GeneSight® testing. 
The results from this study show that the FNP at the clinic is following 
prescribing guidelines for the control group with SSRIs or SNRIs as first line treatment 
(Uphold & Graham, 2013).  The test group were prescribed a variety of medications that 
are appropriate for patients that are having difficulty finding an effective medication.  
There was a lack of follow-up appointments in both the control and test group, but the 
average time for follow-up after medications changes was within the standard time frame. 
There were several patients that did not keep their follow-up appointments as 
scheduled after their initial visit for depression.  The health belief model can be utilized 
to help the provider stress the importance of keeping follow-up appointments for 
depressive disorders.  For the patients that have had missed follow-up appointments, it 
would be important to discuss their perceived severity, benefits, and barriers to coming to 
their scheduled appointments.  By discussing those concepts, the provider may learn that 
the patient doesn’t feel that their depression is severe or that a follow-up appointment is 
needed since they already have a prescription medication.  This would allow the provider 
to educate the patient on why keeping their follow-up appointment is important to their 
plan of care.  Furthermore, the provider could discuss self-efficacy.  This final concept 
could be explained to the patient that there are positive actions they can take on their 




Accurate documentation is important for all clinical sites and providers, especially 
when implementing and analyzing a new evidence-based practice such as 
pharmacogenomic testing.  This research study discovered that the clinical site had 
missing PHQ-9 score documentation that is important to the treatment and evaluation of 
depressive disorders.  This finding was shared and will improve the future documentation 
practices of the clinical site. 
The GeneSight® test provided rational for the prescriber to discontinue a 
medication that one patient was currently trialing due to it being the red category.  This 
suggests that the testing could be a valuable tool for Family Nurse Practitioners to use for 
explaining and justifying medication decisions to patients. Unfortunately, due to the very 
small sample size in this study, no generalizations can be made for any of the study 
variables.  Larger studies of rural family practice clinics have the potential to show a 
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